Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap
Citations Over TimeTop 20% of 2018 papers
Abstract
Asthma-COPD overlap (ACO) is a type of incomplete obstructive airway disease that has a high incidence and mortality. Nevertheless, there is currently no clear definition of ACO and no effective intervention. The newly discovered phosphodiesterase-4 inhibitor, roflumilast, has shown initial efficacy for treating asthma, COPD, and ACO. The mechanism of roflumilast, however, remains unclear, and there has been no interpretation through systematic review to date. The determination of a definite mechanism of roflumilast will guide the clinician's decisions regarding medication use, standardized diagnosis, and treatment guidelines. For this reason, we have systematically reviewed the therapeutic mechanism of roflumilast for ACO and provided reference for the clinical application of roflumilast in ACO.
Related Papers
- → Characterization of Safety With Roflumilast, an Oral Phosphodiesterase-4 Inhibitor for the Treatment of COPD(2010)1 cited
- → Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease(2006)1 cited
- → Oral, Once-Daily Roflumilast and Its Active N-oxide Metabolite Exhibit Dose-Proportional Pharmacokinetics Between 250μg and 500μg(2004)1 cited
- → Efficacy of Roflumilast When Used With Concomitant ICS From the OPUS/RATIO Studies(2010)
- Progress in pharmacological and clinical studies of the phosphodiesterase 4 inhibitor roflumilast(2011)